Eikon Therapeutics (EIKN) has upcoming FDA regulatory milestones for EIK1006. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Eikon Therapeutics (EIKN).
Over the past two years, Eikon Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
EIK1006 and EIK1001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
EIK1006 FDA Regulatory Events
EIK1006 is a drug developed by Eikon Therapeutics for the following indication: in Advanced Metastatic Prostate Cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- EIK1006
- Announced Date:
- November 17, 2026
- Target Action Date:
- H2 2027
- Estimated Target Date Range:
- July 1, 2027 - December 31, 2027
- Indication:
- in Advanced Metastatic Prostate Cancer
Announcement
Eikon Therapeutics, Inc. announced that Initial clinical data from Phase 1/2 study expected in second half of 2027
AI Summary
Eikon Therapeutics plans to begin dosing patients in 2027 in ARGATE-001, a Phase 1/2 study of its experimental prostate cancer drug EIK1006. The company expects initial clinical data in the second half of 2027. The study will assess the drug’s safety, tolerability, and early signs of effectiveness in people with advanced metastatic prostate cancer whose disease has progressed despite anti-hormonal treatment.
EIK1006 is designed to block the androgen receptor, a protein that can help prostate cancer grow. It targets both the normal form of the receptor and genetic changes linked to resistance to conventional treatments, including receptor amplification and mutations. In preclinical research, the drug was shown to bind the receptor and interfere with its activity. The study will explore whether this approach can help address a serious need for patients whose cancer no longer responds to established therapies. Its potential benefits and risks will need to be assessed in clinical trials.
Read Announcement- Drug:
- EIK1006
- Announced Date:
- November 17, 2026
- Indication:
- in Advanced Metastatic Prostate Cancer
Announcement
ikon Therapeutics, announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. Inc.
AI Summary
Eikon Therapeutics said the FDA has cleared its Investigational New Drug application for EIK1006, allowing the company to begin clinical testing in people with advanced metastatic prostate cancer. Eikon plans to launch ARGATE-001, a Phase 1/2 study, in 2027. The trial will assess the drug’s safety, tolerability, and early signs of effectiveness in patients whose cancer has progressed despite established hormone-based treatment.
EIK1006 is designed to block the androgen receptor, a protein that can help prostate cancer grow. It is intended to act against both the normal receptor and important genetic changes linked to resistance to existing treatments. In preclinical research, the drug bound to the receptor and blocked its movement into the cell nucleus, reducing related signaling. These findings do not establish that it will benefit patients. Eikon expects to begin dosing participants in 2027 and report initial safety and efficacy results in the second half of that year. The company says treatment resistance remains a major challenge for these patients.
Read Announcement
EIK1001 FDA Regulatory Timeline and Events
EIK1001 is a drug developed by Eikon Therapeutics for the following indication: patients with stage IV NSCLC.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- EIK1001
- Announced Date:
- October 26, 2026
- Indication:
- patients with stage IV NSCLC
Announcement
Eikon Therapeutics announced Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced NSCLC demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies.
Read Announcement- Drug:
- EIK1001
- Announced Date:
- October 18, 2026
- Indication:
- patients with stage IV NSCLC
Announcement
Eikon Therapeutics, Inc announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026..
AI Summary
Eikon Therapeutics announced that seven full-text abstracts on four clinical candidates will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, starting October 23. The presentations will share new findings and progress across the company’s cancer-drug pipeline.
For EIK1001, a treatment designed to activate immune responses, researchers will report updated results from a Phase 2 lung cancer study combining it with pembrolizumab and chemotherapy, and outline a planned Phase 2/3 trial. EIK1003, a PARP1 inhibitor, will be discussed in studies testing it alone or with paclitaxel in advanced cancers, and with abiraterone in metastatic prostate cancer. EIK1004, a related inhibitor designed to enter the brain, will have initial findings presented from a study in advanced tumors.
For EIK1005, a Werner helicase inhibitor, the company will present early safety, tolerability, and drug-level data, alongside plans to study it alone and with pembrolizumab. Most presentations are scheduled for October 23, with EIK1001 sessions on October 26.
Read Announcement- Drug:
- EIK1001
- Announced Date:
- August 11, 2026
- Indication:
- patients with stage IV NSCLC
Announcement
Eikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial.
AI Summary
Eikon Therapeutics selected a dose of 0.60 mg/m² for EIK1001 in its TeLuRide-006 trial. Going forward, all participants randomized to receive EIK1001 will receive this dose. The decision followed a planned review of unblinded trial data and matched a recommendation from the study’s independent Data Monitoring Committee (DMC). The DMC also recommended that the trial continue as planned in all other respects.
TeLuRide-006 is a global Phase 2/3 study testing EIK1001 or placebo, each combined with pembrolizumab, as first-line treatment for advanced cutaneous melanoma. EIK1001 is designed to activate immune responses that may help the body fight cancer. Eikon says choosing the dose advances its study of the drug in combination with checkpoint inhibitors. The company’s chief medical officer noted that better treatments are still needed for people with advanced melanoma. EIK1001 remains investigational; the announcement does not report trial results showing that it is effective or safe.
Read Announcement- Drug:
- EIK1001
- Announced Date:
- July 27, 2026
- Indication:
- patients with stage IV NSCLC
Announcement
Eikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).
AI Summary
Eikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational clinical trial of EIK1001. The study is evaluating EIK1001 in combination with pembrolizumab and chemotherapy selected for the patient’s cancer type. It is designed for patients with newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) who have not previously received treatment for advanced disease.
The trial will assess whether this combination can provide a meaningful treatment option for people with advanced NSCLC. As a registrational study, its results could support future regulatory applications if the treatment is shown to be safe and effective. Eikon noted that statements about the trial and EIK1001’s potential are forward-looking and involve risks and uncertainties. The company said these statements reflect information available at the time of the announcement and may not be updated unless required by law.
Read Announcement- Drug:
- EIK1001
- Announced Date:
- July 20, 2026
- Indication:
- patients with stage IV NSCLC
Announcement
Eikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
AI Summary
Eikon Therapeutics announced that seven abstracts from its clinical pipeline were accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid. The updates cover several lead programs, including EIK1001, EIK1003, EIK1004, and EIK1005, across a range of cancers.
For EIK1001, the company will share Phase 2 results in stage IV non-small cell lung cancer, including data from the squamous cohort, as well as a Phase 2/3 study combining the drug with pembrolizumab and chemotherapy. EIK1003 data will include studies in metastatic prostate cancer and advanced solid tumors. EIK1004 will be presented as a first-in-human study in patients with advanced solid tumors carrying HRR mutations. EIK1005 presentations will cover its use as a monotherapy and with pembrolizumab, along with safety, tolerability, and pharmacokinetic findings.
The company said the abstracts reflect progress across its pipeline, but noted that forward-looking statements should not be relied on too heavily.
Read Announcement